The adverse reactions of bevacizumab in combination with the FOLFOX chemotherapy regimen in metastatic colorectal cancer
Combination therapy demonstrates manageable safety with early monitoring, though stricter criteria for ADR detection may overlook rare events. Key risks align with monotherapy profiles, emphasizing vigilance for infection-related and gastrointestinal complications. Further studies are warranted to validate these pharmacovigilance findings.
Authors
- Jiyuan Zheng (ORCID: https://orcid.org/0000-0003-3735-1309)
- Shulan Huang
- Zilan Zhong (ORCID: https://orcid.org/0009-0000-3750-3005)
- Bingshuo Liu
- Bohui Zheng
- JiaZhen Jiang
- Wenxiang Zeng (ORCID: https://orcid.org/0009-0001-0114-8379)
- DongQiang Luo
Institutions
- Guangzhou University of Chinese Medicine (CN)
- Nanchang University (CN)
- Southern Medical University (CN)
Publication Details
- Journal
- Expert Opinion on Drug Safety
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1080/14740338.2025.2490274
- Citations
- 1
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.05